Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755), a Chinese pharmaceutical company, has registered a Phase III clinical study with Clinicaltrials.gov for its Claudin18.2-targeted antibody ASKB589. The trial will investigate the use of ASKB589 in combination with tislelizumab and chemotherapy as a first-line treatment for advanced gastric cancer. The study aims to enroll 780 patients with advanced recurrent or metastatic gastric cancer and is anticipated to complete by the end of 2026.
ASKB589 is an in-house developed antibody designed to enhance antibody-dependent cellular cytotoxicity (ADCC) and targets the CLDN18.2 antigen. Currently, there is no similar product approved globally. Tislelizumab, from BeiGene, is a programmed death-1 (PD-1) inhibitor that has received approval for 12 indications in China.- Flcube.com
